ArticleCureus2025
Safety Evaluation of Omniscan: An Observational Postmarketing Surveillance.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to conduct a single-arm, open-label, multicenter postmarketing surveillance study to evaluate the safety of Omniscan immediately and six weeks (± two weeks) after injection.
methodsThree sites in India that use Omniscan (gadodiamide; GE Healthcare, Chicago, IL) as a contrast agent were selected. Omniscan is a linear, nonionic, nonprotein-binding gadolinium-based contrast agent. A total of 150 study participants were enrolled for contrast-enhanced magnetic resonance imaging (CE-MRI). All patients were asked for permission to be contacted six weeks (± two weeks) after CE-MRI, and participants were telephonically followed up by a healthcare professional with a questionnaire.
resultsOf the 150 enrolled participants, 133 (89%) completed the telephonic follow-up, scheduled for six weeks (± two weeks) after injection. Of these 133 participants, a total of seven (5.26%) treatment-emergent adverse events (TEAEs) were reported. Out of these seven TEAEs, one TEAE (0.007%) was serious, with seriousness criteria life-threatening. A single event was severe; the remaining adverse events (AEs) were of mild severity. None of the AEs was assessed as related to Omniscan.
conclusionsThere were no AEs causally related to Omniscan (gadodiamide) immediately after injection and during telephonic follow-up after six weeks (± two weeks). Safety analysis in this postmarketing surveillance did not reveal any increase in the safety risk of Omniscan. No AE persisted for four weeks or more after injection of Omniscan for MRI. CE-MRI with Omniscan was thus generally considered safe and well-tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.